The latest price target for NeuroSense Therapeutics (NASDAQ:NRSN) was reported by Alliance Global Partners on July 17, 2023. The analyst firm set a price target for $7.50 expecting NRSN to rise to within 12 months (a possible 913.51% upside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for NeuroSense Therapeutics (NASDAQ:NRSN) was provided by Alliance Global Partners, and NeuroSense Therapeutics initiated their buy rating.

There is no last upgrade for NeuroSense Therapeutics

There is no last downgrade for NeuroSense Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of NeuroSense Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for NeuroSense Therapeutics was filed on July 17, 2023 so you should expect the next rating to be made available sometime around July 17, 2024.

While ratings are subjective and will change, the latest NeuroSense Therapeutics (NRSN) rating was a initiated with a price target of $0.00 to $7.50. The current price NeuroSense Therapeutics (NRSN) is trading at is $0.74, which is within the analyst’s predicted range.